目的 探讨利拉鲁肽对2型糖尿病非酒精性脂肪性肝病患者肝脂肪含量及血浆脂联素、FGF-21的影响.方法选取该院2015年1月—2017年1月收治的82例2型糖尿病NAFLD患者,均经临床检查确诊,根据不同治疗方法分为两组,观察组(n=41)给予利拉鲁肽治疗,对照组(n=41)给予胰岛素治疗,对比两组患者治疗前后FGF-21、脂联素、肝脂肪含量.结果 治疗前两组患者FGF-21、脂联素、肝脂肪含量对比差异无统计学意义(P＞0.05);治疗后观察组患者FGF-21、肝脂肪含量明显低于对照组,脂联素明显高于对照组(P＜0.05).结论 利拉鲁肽不仅具备控制血糖的效果,还能有效降低肝脏脂肪和FGF-21含量,提高脂联素水平,值得临床推广.%Objective To study the effect of liraglutide on the liver fat content and plasma adiponectin and FGF-21 of patients with non-alcoholic fatty liver disease in type 2 diabetes mellitus. Methods 82 cases of patients with with non-alcoholic fatty liver disease in type 2 diabetes admitted and treated in our hospital from January 2015 to January 2017 were selected and divided into two groups according to different treatment methods, with 41 cases in each, the observation group and the control group were respectively treated with liraglutide and insulin, and the FGF-21, adiponectin and liver fat content before and after treatment were compared between groups. Results Before treatment, the differences in the FGF-21, adiponectin and liver fat content between groups were not statistically significant (P＞0.05), after treatment, the FGF-21 and liver fat content in the observation group were obviously lower than those in the control group, and the adiponectin was obviously higher than that in the control group (P＜0.05). Conclusion The liraglutide can control the blood glucose and also reduce the live fat and FGF-21 contant, and improve the adiponectin level, and it is worth clinical promotion.
展开▼
